• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·019175.KS
Share

Shinpoong Pharmaceutical Co.,Ltd Stocks

₩ 14290Last Updated 19.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

₩ 283.98M

₩ 14290
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shinpoong Pharmaceutical Co., Ltd., a South Korean firm, specializes in the production and distribution of a broad spectrum of pharmaceutical goods. Its product offerings span various therapeutic categories, including cephalosporin and penicillin antibiotics, as well as a range of finished drug formulations. The company further supplies active pharmaceutical ingredients (APIs) and specialized medications like Pyramax, an anti-malarial treatment. Additionally, Shinpoong develops drugs for conditions such as hypercholesterolemia, knee osteoarthritis, shoulder periarthritis, and for preventing surgical adhesion, alongside its over-the-counter (OTC) products. With a notable international footprint, Shinpoong Pharmaceutical exports its remedies to approximately 50 countries globally. This company, established in 1962, is headquartered in Seoul, South Korea.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA, trading

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

19.10.2026 13:25

Burry Compared the Next Crash to a Supervolcano Eruption: 5 Signs for Investors

19.10.2026 13:13

French government bonds fell in value amid mass protests and a budget crisis

19.10.2026 11:10

Big Tech Held Hostage: How the Worst-Case Scenario with CoreWeave Might Unfold

19.10.2026 10:47

Top Stories This Morning: Fears of a Crisis in Europe; Treasuries Regain Their Status as a Safe Haven

19.10.2026 10:31

Tesla and Meta Earnings Reports, PMI Data in the U.S. and Europe: What Investors Can Expect This Week

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026